Cantani A, Businco E, Benincori N, de Angelis M, di Fazio A, Businco L
Ann Allergy. 1984 Jul;53(1):79-84.
The clinical course of 87 children with pollen induced rhinitis or both rhinitis and asthma was followed in a prospective controlled study over a three year period. All children were treated with specific IT. The long term results have shown that IT was successful in 94% of children with asthma and rhinitis and 90% with rhinitis given more than 80,000 PNU. By contrast, the outcome of 78 selected controls also followed during the same period who did not receive IT was almost exactly the opposite. In addition to demonstrating the clinical effectiveness of IT, the authors stress the relationship among successful results, highest tolerated doses, and larger cumulative dosage which is irrespective of the duration of the therapy. The authors also discuss whether the children in the control group should be injected with placebo solutions or treated with all available medication.
在一项前瞻性对照研究中，对87名患有花粉诱发鼻炎或同时患有鼻炎和哮喘的儿童进行了为期三年的临床病程跟踪。所有儿童均接受特异性免疫治疗（IT）。长期结果表明，对于接受超过80,000 PNU治疗的哮喘合并鼻炎儿童，IT的成功率为94%，鼻炎儿童为90%。相比之下，同期选取的78名未接受IT治疗的对照儿童的结果几乎完全相反。除了证明IT的临床有效性外，作者强调了成功结果、最高耐受剂量和更大累积剂量之间的关系，而这与治疗持续时间无关。作者还讨论了对照组儿童是否应注射安慰剂溶液或接受所有可用药物治疗。
